233 related articles for article (PubMed ID: 25234661)
1. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.
Faurschou M; Mellemkjaer L; Voss A; Keller KK; Hansen IT; Baslund B
Rheumatology (Oxford); 2015 Aug; 54(8):1345-50. PubMed ID: 25234661
[TBL] [Abstract][Full Text] [Related]
2. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
[TBL] [Abstract][Full Text] [Related]
3. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Heijl C; Harper L; Flossmann O; Stücker I; Scott DG; Watts RA; Höglund P; Westman K; Mahr A;
Ann Rheum Dis; 2011 Aug; 70(8):1415-21. PubMed ID: 21616914
[TBL] [Abstract][Full Text] [Related]
4. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis.
Knight A; Askling J; Ekbom A
Int J Cancer; 2002 Jul; 100(1):82-5. PubMed ID: 12115591
[TBL] [Abstract][Full Text] [Related]
5. Leukemia and myelodysplastic syndrome in granulomatosis with polyangiitis: subtypes, clinical characteristics, and outcome.
Knight A; Hjorton K; Sundström C; Höglund M; Backlin C; Smedby KE; Askling J; Baecklund E
J Rheumatol; 2015 Apr; 42(4):690-4. PubMed ID: 25641890
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.
Shang W; Ning Y; Xu X; Li M; Guo S; Han M; Zeng R; Ge S; Xu G
PLoS One; 2015; 10(5):e0126016. PubMed ID: 25973882
[TBL] [Abstract][Full Text] [Related]
8. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
Knight A; Askling J; Granath F; Sparen P; Ekbom A
Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
[TBL] [Abstract][Full Text] [Related]
9. Impact of pre-existing co-morbidities on mortality in granulomatosis with polyangiitis: a cohort study.
Faurschou M; Ahlström MG; Lindhardsen J; Baslund B; Obel N
Rheumatology (Oxford); 2016 Apr; 55(4):649-53. PubMed ID: 26615030
[TBL] [Abstract][Full Text] [Related]
10. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.
Dreyer L; Faurschou M; Mogensen M; Jacobsen S
Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088
[TBL] [Abstract][Full Text] [Related]
11. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
12. The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis.
Calatroni M; Buzio C; Vaglio A
Rheumatology (Oxford); 2015 Aug; 54(8):1339-41. PubMed ID: 26018438
[No Abstract] [Full Text] [Related]
13. Implantable cardioverter-defibrillators and subsequent cancer risk: a nationwide population-based cohort study.
Pedersen SB; Nielsen JC; Bøtker HE; Farkas DK; Schmidt M; Sørensen HT
Europace; 2015 Jun; 17(6):902-8. PubMed ID: 25840286
[TBL] [Abstract][Full Text] [Related]
14. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
15. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013.
Rahmattulla C; Berden AE; Wakker SC; Reinders ME; Hagen EC; Wolterbeek R; Bruijn JA; Bajema IM
Arthritis Rheumatol; 2015 Dec; 67(12):3270-8. PubMed ID: 26246307
[TBL] [Abstract][Full Text] [Related]
17. Risk of Diabetes Mellitus among Patients Diagnosed with Giant Cell Arteritis or Granulomatosis with Polyangiitis: Comparison with the General Population.
Faurschou M; Ahlström MG; Lindhardsen J; Obel N; Baslund B
J Rheumatol; 2017 Jan; 44(1):78-83. PubMed ID: 27744394
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk among Danish women with cosmetic breast implants.
Friis S; Hölmich LR; McLaughlin JK; Kjøller K; Fryzek JP; Henriksen TF; Olsen JH
Int J Cancer; 2006 Feb; 118(4):998-1003. PubMed ID: 16152592
[TBL] [Abstract][Full Text] [Related]
19. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
van Daalen EE; Rizzo R; Kronbichler A; Wolterbeek R; Bruijn JA; Jayne DR; Bajema IM; Rahmattulla C
Ann Rheum Dis; 2017 Jun; 76(6):1064-1069. PubMed ID: 27899372
[TBL] [Abstract][Full Text] [Related]
20. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
